These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 19049640)

  • 1. Binding of human papillomavirus type 16 to heparan sulfate is inhibited by mucosal antibodies from patients with low-grade squamous intraepithelial lesions but not from cervical cancer patients.
    Lopez TV; Cancio C; Cruz-Talonia F; Ruiz B; Sapp M; Rocha-Zavaleta L
    FEMS Immunol Med Microbiol; 2008 Nov; 54(2):167-76. PubMed ID: 19049640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia.
    de Gruijl TD; Bontkes HJ; Walboomers JM; Schiller JT; Stukart MJ; Groot BS; Chabaud MM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
    J Natl Cancer Inst; 1997 May; 89(9):630-8. PubMed ID: 9150187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of human papillomavirus genotypes, and mucosal IgA anti-viral responses in women with cervical ectopy.
    Monroy OL; Aguilar C; Lizano M; Cruz-Talonia F; Cruz RM; Rocha-Zavaleta L
    J Clin Virol; 2010 Jan; 47(1):43-8. PubMed ID: 19906557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus 16/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational study.
    Velentzis LS; Sitas F; O'Connell DL; Darlington-Brown J; Egger S; Sinha R; Banks E; Frazer IH; Canfell K
    BMC Infect Dis; 2014 Dec; 14():3861. PubMed ID: 25528152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in women with squamous intraepithelial lesions.
    Strickler HD; Schiffman MH; Eklund C; Glass AG; Scott DR; Sherman ME; Wacholder S; Kurman RJ; Manos MM; Schiller JT; Dillner J
    Cancer Epidemiol Biomarkers Prev; 1997 Mar; 6(3):183-8. PubMed ID: 9138661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody responses to HPV16 virus-like particles in women with cervical intraepithelial neoplasia infected with a variant HPV16.
    Ellis JR; Etherington I; Galloway D; Luesley D; Young LS
    Lancet; 1997 Apr; 349(9058):1069-70. PubMed ID: 9107250
    [No Abstract]   [Full Text] [Related]  

  • 7. Mucosal IgG and IgA responses to human papillomavirus type 16 capsid proteins in HPV16-infected women without visible pathology.
    Rocha-Zavaleta L; Pereira-Suarez AL; Yescas G; Cruz-Mimiaga RM; Garcia-Carranca A; Cruz-Talonia F
    Viral Immunol; 2003; 16(2):159-68. PubMed ID: 12828867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlates of cervical mucosal antibodies to human papillomavirus 16: results from a case control study.
    Bierl C; Karem K; Poon AC; Swan D; Tortolero-Luna G; Follen M; Wideroff L; Unger ER; Reeves WC
    Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S262-8. PubMed ID: 16229879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection.
    Haupt RM; Wheeler CM; Brown DR; Garland SM; Ferris DG; Paavonen JA; Lehtinen MO; Steben M; Joura EA; Giacoletti KE; Radley DR; James MK; Saah AJ; Sings HL;
    Int J Cancer; 2011 Dec; 129(11):2632-42. PubMed ID: 21491420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids.
    Sasagawa T; Rose RC; Azar KK; Sakai A; Inoue M
    Int J Cancer; 2003 Apr; 104(3):328-35. PubMed ID: 12569556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of antibody to E2 protein of human papillomavirus and p16
    Chuerduangphui J; Pientong C; Swangphon P; Luanratanakorn S; Sangkomkamhang U; Tungsiriwattana T; Kleebkaow P; Burassakarn A; Ekalaksananan T
    Med Oncol; 2018 May; 35(6):93. PubMed ID: 29744680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local applications of GM-CSF induce the recruitment of immune cells in cervical low-grade squamous intraepithelial lesions.
    Hubert P; Doyen J; Capelle X; Arafa M; Renoux V; Bisig B; Seidel L; Evrard B; Bousarghin L; Gerday C; Boniver J; Foidart JM; Delvenne P; Jacobs N
    Am J Reprod Immunol; 2010 Aug; 64(2):126-36. PubMed ID: 20367631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HPV-16 E7-Specific Cellular Immune Response in Women With Cervical Intraepithelial Lesion Contributes to Viral Clearance: A Cross-Sectional and Longitudinal Clinical Study.
    Zhang L; Shi X; Zhang Q; Mao Z; Shi X; Zhou J; Jian A; Zhu R; Jiang S; Lu W
    Front Immunol; 2021; 12():768144. PubMed ID: 35095843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).
    Kaufmann AM; Nieland JD; Jochmus I; Baur S; Friese K; Gabelsberger J; Gieseking F; Gissmann L; Glasschröder B; Grubert T; Hillemanns P; Höpfl R; Ikenberg H; Schwarz J; Karrasch M; Knoll A; Küppers V; Lechmann M; Lelle RJ; Meissner H; Müller RT; Pawlita M; Petry KU; Pilch H; Walek E; Schneider A
    Int J Cancer; 2007 Dec; 121(12):2794-800. PubMed ID: 17721997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of human papillomavirus type 16/18 genotyping in predicting high-grade cervical/vaginal intraepithelial neoplasm in women with mildly abnormal Papanicolaou results.
    Guo M; Gong Y; Wang J; Dawlett M; Patel S; Liu P; Bevers TB; Sneige N
    Cancer Cytopathol; 2013 Feb; 121(2):79-85. PubMed ID: 23225501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physical and methylation status of human papillomavirus 16 in asymptomatic cervical infections changes with malignant transformation.
    Dutta S; Chakraborty C; Dutta AK; Mandal RK; Roychoudhury S; Basu P; Panda CK
    J Clin Pathol; 2015 Mar; 68(3):206-11. PubMed ID: 25563334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgG antibodies to human papillomavirus 16, 52, 58, and 6 L1 capsids: case-control study of cervical intraepithelial neoplasia in Japan.
    Matsumoto K; Yoshikawa H; Yasugi T; Nakagawa S; Kawana K; Takeoka A; Yaegashi N; Iwasaka T; Kanazawa K; Taketani Y; Kanda T
    J Med Virol; 2003 Mar; 69(3):441-6. PubMed ID: 12526056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV16-L1-specific antibody response is associated with clinical remission of high-risk HPV-positive early dysplastic lesions.
    Mehlhorn G; Hautmann SK; Koch MC; Strehl JD; Hartmann A; Hilfrich R; Beckmann MW; Griesser H
    Anticancer Res; 2014 Sep; 34(9):5127-32. PubMed ID: 25202103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local cervical immunity in women with low-grade squamous intraepithelial lesions and immune responses after abrasion.
    Ekalaksananan T; Malat P; Pientong C; Kongyingyoes B; Chumworathayi B; Kleebkaow P
    Asian Pac J Cancer Prev; 2014; 15(10):4197-201. PubMed ID: 24935370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological implications of human papilloma virus (HPV) L1 capsid protein immunoreactivity in HPV16-positive cervical cytology.
    Lee SJ; Lee AW; Kang CS; Park JS; Park DC; Ki EY; Lee KH; Yoon JH; Hur SY; Kim TJ
    Int J Med Sci; 2014; 11(1):80-6. PubMed ID: 24396289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.